Download Meningococcal Disease Presentation Slides

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Seven Countries Study wikipedia , lookup

Huntington's disease wikipedia , lookup

Behçet's disease wikipedia , lookup

Kawasaki disease wikipedia , lookup

Disease wikipedia , lookup

2001 United Kingdom foot-and-mouth outbreak wikipedia , lookup

Transcript
What is meningococcal disease?
 Adolescents and young adults are at increased risk of meningococcal disease,
often referred to as meningitis, a serious bacterial infectious disease that can
lead to lifelong complications and even death
 Symptoms usually progress very quickly and may include some combination
of high fever, headache, stiff neck, confusion, nausea, vomiting, exhaustion,
and purplish rash

Students who experience these symptoms, especially if they are unusually
sudden, progressive, or severe, should be examined as soon as possible by a
healthcare professional
 The bacteria that cause the disease, Neisseria meningitidis, are spread by
contact with saliva or spit during close or lengthy contact (e.g., sharing
drinking glasses or kissing)
Why should you be concerned about serogroup B?
 It is the most common cause of meningococcal disease in US
adolescents and young adults and caused recent college
outbreaks
 Approximately one out of every 10 people who get the disease
will die
 Two in 10 will suffer serious and permanent complications
including brain damage, kidney damage, hearing loss, and
amputation of limbs
 The routinely recommended quadrivalent vaccine (ACWY) does
not protect against serogroup B
How can it be prevented?
 Vaccination is the best protection against the disease. There are two kinds of
vaccines currently available:

Routine vaccination with a quadrivalent vaccine that protects against four major
meningococcal serogroups (A, C, W, and Y) is recommended for all adolescents at
age 11-12 years, with a booster dose at age 16 years

Meningococcal serogroup B vaccination may be recommended by healthcare
professionals for individuals age 16-23 years, with preferred age of 16-18 years
 Talk to a healthcare professional to learn more about meningococcal disease and
vaccines available to help prevent it
 For more information, visit www.nfid.org/meningococcal